Page 59 - MemoriaESP-Eng

www.ciberesp.es

• b F, t Ap, c tM. Antibiotic resistance shaping multi-level population
Most relevant AqueroeDiMoque
biology of bacteriaFront Microbiol. 2013;.
scientific
• yebrA g, DelgADo r, puliDo F, rubio r, gAlán Jc, Moreno s, Holguín A. Different trends
articles
of transmitted HIV-1 drug resistance in Madrid, Spain, among nrisk groups in the last
decade.Arch Virol. 2013;.

• roDríguez-DoMínguez M, puertA t, MenénDez b, gonzález-AlbA JM, roDríguez c, Hellín t,

VerA M, gonzález-sAinz FJ, clAVo p, VillA M, cAntón r, Del roMero J, gAlán Jc. Clinical
and epidemiological characterization of a lymphogranuloma venereum outbreak in

Madrid, Spain: co-circulation of two variants.Clin Microbiol Infect. 2013;20:219-225.

• noVAis c, FreitAs Ar, silVeirA e, Antunes p, silVA r, coque tM, peixe l. Spread of multi-
drug-resistant Enterococcus to animals and humans: an underestimated role for the

pig farm environmentJ Antimicrob Chemother. 2013;68:2746-2754.

• cAstillA J, goDoy p, DoMínguez A, MArtínez-bAz i, AstrAy J, MArtín V, DelgADo-roDríguez M,
b M, s n, M JM, q JM, g Jc, c A, g-c
AricotolDeVilAAyorAluintAnAAlánAstroonzálezAnDelAs
F, gArín o, sAez M, tAMAMes s, puMArolA t; CIBERESP Cases and Controls in Influenza

Working Group Spain (Caylà JA). Influenza vaccine effectiveness in preventing out-
patient, inpatient, and severe cases of laboratory-confirmed influenzaCLIN INFECT

DIS. 2013;57(2):167-175.

The Group CIBERESP G-33, MSP-RYC was partially funded in 2013 by three Pro-
Highlights
jects of the EU Commission (PAR-241476; EVOTAR-F3-2011-282004; R-GNO-

SIS-282512), and was accepted as a group in the 8th Call IMI. Ref: ENABLE
– 115583 Project; as far as Spanish funding is concerned it has 8 active Pro-

jects (PI10-02588; PS09/02381; PS09/00284; PCAPE 2011_0025; PI12/00240;
PROMPT-S2010/BMD-2414; PI12-01581; PI12-00567). The Group has been in-

volved in the Scientific Research Group of the EU Commision producing the Docu-

ment “Joint Programming Initiative on Antibiotic Resistance” (Dr. Baquero), in
the Report on EFSA Panel on Biological Hazards (BIOHAZ) (Dr. Coque), and in

the Report on Primary Resistances to Antiretrovirals in El Salvador (Ministry for

Health and Social Policy of El Salvador). Relations with Pharma and Diagnostic-
Technological Industries were: participation in the studies CENIT (CUBIST); E

ß-Protocol Xpert (CEPHEID); IDI-20120242 (CDTI), and EC11-131. Dr. Baquero
was invited as Key-Note Speaker in the ICAAC Conference of the ASM (Denver,

USA), lecturing on “A Vision of Antimicrobial Therapy for the Future” which was

broadly disseminated in the Web (You Tube). The Group has generated 34 publica-
tions in peer-reviewed journals, 68 communications to scientific conferences, and

14 Invited lectures including lectures the Emory School of Public Health (Atlanta,

Georgia, USA), the Darwin Summit in Galapagos Islands about Global Evolution
and Antibiotic Resistance –Does Evolution Matter?, and the B-Debate (Bio-Cat)

and the Barcelona Institute for Global Health (ISGlobal) “On the Global Threat of 13
Antimicrobial resistance: Science for Intervention”. During the year, the Group is 20
T
progressively shifting from basic molecular biology of pathogens to evolutionary OR
P
and population biology applications to public health in the broad perspective of RE
Public Health Microbiology.
L
A
NU
N
A
P /
S
RE
E
IB
C

59